



ASSOCIAZIONE SENONETWORK ITALIA
IL NETWORK DEI CENTRI ITALIANI DI SENOLOGIA



“Senonetwork: incontro centri di senologia 7.0”

Terapia Neoadiuvante

Michelino De Laurentiis

Istituto Nazionale Tumori «Fondazione Pascale»

Napoli - ITALY



Disclosures


- Fees for Talk or Consultation
 - Astrazeneca, Amgen, Arvinas, Celgene, Daiichi-Sankyo, Eisai, Eli-Lilly, Exact Science, Gilead, Istituto Gentili, Menarini-Stemline, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi-Aventis, Seagen, Sophos, Veracyte



Scopo della Terapia Neoadiuvante

**Achieve
Operability**


LABC



'70s

**Improve Breast
Conservation**

T > 5 cm



'80s


Neo-adj





Scopo della Terapia Neoadiuvante







➤ Evaluate Treatment sensitivity






Scopo della Terapia Neoadiuvante

- Identification of early markers of response
- Understanding mechanisms of resistance






Treatment Escalation in Non-pCR HER2+ EBC






Treatment Escalation in Non-pCR TNBC






Treatment Escalation in Non-pCR BRCAm





KEYNOTE-522 Study Design (NCT03036488)



Neoadjuvant phase: starts from the first neoadjuvant treatment and ends after definitive surgery (post treatment included)

Adjuvant phase: starts from the first adjuvant treatment and includes radiation therapy as indicated (post treatment included)


^aMust consist of at least 2 separate tumor cores from the primary tumor.
^bCarboplatin dose was AUC 5 Q3W or AUC 1.5 QW.
^cPaclitaxel dose was 80 mg/m² QW.

^dDoxorubicin dose was 60 mg/m² Q3W.
^eEpirubicin dose was 90 mg/m² Q3W.
^fCyclophosphamide dose was 600 mg/m² Q3W.





Statistically Significant and Clinically Meaningful EFS at IA4



	Events	HR (95% CI)	P-value
Pembro + Chemo/Pembro	15.7%	0.63 ^a (0.48-0.82)	0.00031 ^b
Pbo + Chemo/Pbo	23.8%		

No. at Risk

Months	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51
Pembro + Chemo/Pembro	784	781	769	751	728	718	702	692	681	671	652	551	433	303	165	28	0	0
Pbo + Chemo/Pbo	390	386	382	368	358	342	328	319	310	304	297	250	195	140	83	17	0	0

^aHazard ratio (CI) analyzed based on a Cox regression model with treatment as a covariate stratified by the randomization stratification factors. ^bPrespecified P-value boundary of 0.00517 reached at this analysis.

^cDefined as the time from randomization to the data cutoff date of March 23, 2021.




Treatment

* Biology that requires ChT (TNBC, HER2-positive, luminal B-like), to assess response and prognosis and eventually decide on postoperative therapies, should preferentially receive preoperative ChT

** Aggressive phenotypes: TNBC or HER2-positive breast cancer

† If ChT is planned, it should all be given as neoadjuvant

‡ Concomitant postoperative RT, postoperative ET and anti-HER2 therapy



Allegato 3

RE

RETE ONCOLOGICA REGIONE CAMPANIA

VOLUMI MINIMI CHIRURGICI SEDI SPECIFICI INDICATI PER LA PARTECIPAZIONE ALLA RETE ONCOLOGICA REGIONE CAMPANIA - FASE DI TRANSIZIONE

SEDE TUMORALE	VOLUMI CHIRURGICI DI RIFERIMENTO - n° pazienti		VOLUMI MINIMI FASE DI TRANSIZIONE *** n.° pazienti		
	CUT OFF RIFERIMENTO *	CUT OFF ridotto (20%) **	1° anno - 2022	2° anno - 2023	3° anno - 2024
MAMMELLA	150	120	60	84	120

Centri di Senologia:

n.22 individuati dalla Regione
n.7 aderenti a Senonetwork

PDTA Regionale ca Mammario Operabile



Tumore della mammella localizzato, operabile


NB: i tumori HER2+ e Triplo-negativi ≥ 2 cm seguono percorso della malattia localmente avanzata (Figura 5)

Chirurgia radicale*


Radioterapia adiuvante, secondo le linee guida

Chemioterapia/ Terapia target/
Ormonoterapia adiuvante, secondo le linee guida

PDTA Regionale ca Mammario Operabile



PDTA Regionale ca Mammario Operabile



Aderenza al PDTA Regionale x Neoadiuvante



INT IRCCS Pascale

100% Ca Mammario Precoce valutati al GOM Pre-Operatorio



80% Ca Mammario Precoce valutati al GOM Pre-Operatorio
(autodichiarazione dei centri)